Vanda Pharmaceuticals Inc.
Index- P/E97.41 EPS (ttm)0.11 Insider Own1.30% Shs Outstand56.58M Perf Week4.60%
Market Cap641.94M Forward P/E22.73 EPS next Y0.48 Insider Trans-2.15% Shs Float54.52M Perf Month5.82%
Income6.50M PEG2.70 EPS next Q0.08 Inst Own- Short Float / Ratio4.46% / 6.69 Perf Quarter5.11%
Sales257.90M P/S2.49 EPS this Y37.70% Inst Trans-1.73% Short Interest2.43M Perf Half Y7.49%
Book/sh9.11 P/B1.20 EPS next Y860.00% ROA1.10% Target Price11.00 Perf Year-34.16%
Cash/sh7.73 P/C1.41 EPS next 5Y36.10% ROE1.30% 52W Range9.24 - 18.00 Perf YTD-30.47%
Dividend- P/FCF13.21 EPS past 5Y27.80% ROI6.50% 52W High-39.39% Beta0.52
Dividend %- Quick Ratio5.50 Sales past 5Y13.00% Gross Margin90.60% 52W Low18.07% ATR0.38
Employees278 Current Ratio5.50 Sales Q/Q-6.80% Oper. Margin3.20% RSI (14)58.03 Volatility3.66% 3.92%
OptionableYes Debt/Eq0.00 EPS Q/Q-57.90% Profit Margin2.50% Rel Volume0.69 Prev Close10.96
ShortableYes LT Debt/Eq0.00 EarningsNov 02 AMC Payout0.00% Avg Volume363.26K Price10.91
Recom3.00 SMA203.29% SMA506.27% SMA2002.51% Volume251,195 Change-0.46%
Feb-25-22Downgrade Jefferies Buy → Hold $24 → $12
May-12-21Initiated BofA Securities Buy $22
Jan-14-21Downgrade Citigroup Buy → Neutral $14
Oct-29-20Upgrade Citigroup Neutral → Buy $14
Jun-09-20Downgrade Citigroup Buy → Neutral $14
Mar-16-20Downgrade Oppenheimer Perform → Underperform
Mar-12-20Upgrade Citigroup Neutral → Buy $14
Nov-07-19Downgrade Citigroup Buy → Neutral $19
Aug-01-19Upgrade Citigroup Neutral → Buy $19
Jul-25-19Downgrade Stifel Buy → Hold $26 → $17
Show Previous Ratings
Dec-02-22 07:00AM
Nov-09-22 05:28AM
Nov-08-22 08:30PM
Nov-03-22 03:24PM
Nov-02-22 05:25PM
04:01PM Loading…
Oct-27-22 09:40AM
Oct-26-22 06:00PM
Oct-21-22 02:00PM
Oct-20-22 09:40AM
Oct-18-22 06:50AM
Oct-11-22 09:40AM
Oct-04-22 09:40AM
Sep-29-22 04:30PM
Sep-08-22 06:00PM
06:38PM Loading…
Sep-07-22 06:38PM
Sep-04-22 09:47AM
Aug-03-22 05:25PM
Jul-27-22 05:30PM
Jul-06-22 08:30AM
Jul-05-22 07:21AM
Jun-02-22 04:30PM
May-31-22 06:00PM
May-19-22 07:00PM
May-05-22 07:15PM
May-04-22 04:30PM
Apr-28-22 05:00PM
Apr-27-22 03:03PM
12:47PM Loading…
Mar-28-22 12:47PM
Feb-23-22 04:01PM
Feb-17-22 06:00PM
Feb-09-22 12:25PM
Feb-04-22 12:52PM
Jan-26-22 10:48AM
Jan-24-22 02:48PM
Jan-21-22 05:38PM
Jan-19-22 09:38AM
Jan-18-22 02:41PM
Jan-02-22 04:04PM
Dec-08-21 11:34AM
Nov-10-21 06:30PM
Nov-03-21 10:01PM
Oct-27-21 05:30PM
Oct-23-21 06:08AM
Oct-20-21 03:03PM
Oct-15-21 12:09PM
Oct-14-21 04:30PM
Sep-21-21 12:00PM
Sep-17-21 10:35AM
Sep-07-21 08:30PM
Aug-18-21 03:05PM
Aug-10-21 06:30PM
Aug-05-21 10:00AM
Aug-03-21 01:22PM
Jul-30-21 12:10PM
Jul-29-21 12:32AM
Jul-28-21 08:25PM
Jul-26-21 04:07PM
Jul-23-21 03:26PM
Jul-21-21 04:30PM
Jul-01-21 04:54AM
Jun-30-21 07:42AM
Jun-21-21 08:45PM
Jun-08-21 03:16PM
May-30-21 08:26PM
May-12-21 04:30PM
May-07-21 10:25AM
May-06-21 09:53PM
May-05-21 09:30PM
May-04-21 07:30AM
Apr-29-21 09:01PM
Apr-28-21 12:34PM
Apr-25-21 02:00AM
Apr-20-21 04:30PM
Apr-16-21 10:50PM
Apr-13-21 08:15AM
Apr-06-21 06:40AM
Mar-23-21 07:15AM
Mar-18-21 04:26PM
Mar-17-21 01:56PM
Mar-12-21 10:50PM
Mar-11-21 01:52PM
Feb-23-21 02:49PM
Feb-14-21 01:32PM
Feb-12-21 12:54AM
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Birznieks GuntherSVP, Business DevelopmentAug 26Option Exercise3.121,2503,900190,057Aug 29 05:02 PM
Wijkstrom JoakimSVP, Chief Marketing OfficerAug 22Sale10.273,60537,00796,673Aug 23 05:01 PM
Williams TimothySVP & General CounselAug 15Sale10.308,30085,50495,551Aug 17 04:06 PM
Moran Kevin PatrickSVP, CFO & TreasurerJul 28Sale10.972,23924,562117,452Aug 01 04:45 PM
Mitchell Stephen RayDirectorJun 13Sale9.482,70025,5936,515Jun 14 08:37 PM
Watkins ThomasDirectorJun 02Option Exercise4.1515,00062,25069,505Jun 03 04:31 PM
Watkins ThomasDirectorJun 02Sale9.906,44163,77963,064Jun 03 04:31 PM
DUGAN RICHARD WDirectorMay 31Option Exercise4.1515,00062,25074,887Jun 02 04:47 PM
DUGAN RICHARD WDirectorMay 31Sale9.856,50064,05268,387Jun 02 04:47 PM
Birznieks GuntherSVP, Business DevelopmentMar 02Sale11.2711,517129,792188,807Mar 02 09:26 PM
Wijkstrom JoakimSVP, Chief Marketing OfficerMar 02Sale11.196,97478,060100,278Mar 02 09:28 PM
Williams TimothySVP & General CounselMar 02Sale11.0912,060133,779103,851Mar 02 09:29 PM
Moran Kevin PatrickSVP, CFO & TreasurerMar 02Sale11.288,83299,650119,691Mar 02 09:27 PM
Polymeropoulos Mihael HristosPresident and CEOMar 02Sale11.1529,588329,9451,352,766Mar 02 09:27 PM
Polymeropoulos Mihael HristosPresident and CEOMar 01Sale11.197,50884,0151,382,354Mar 02 09:27 PM
Moran Kevin PatrickSVP, CFO & TreasurerMar 01Sale11.193,47338,863128,523Mar 02 09:27 PM
Birznieks GuntherSVP, Business DevelopmentMar 01Sale11.194,08445,700200,324Mar 02 09:26 PM